Sir,
We have read with interest the two Editorials in the recent issue of the official journal of the Asian Association of Transfusion Medicine (AATM) as written by Shivaram Chandrashekar [1] from Bengaluru, India and Gajendra Gupta [2] from Jaipur, India.
The first Editorial discusses the issue "Blood Banker's Ethical Dilemma: To Assure Quality or Contain Costs" and the second discusses the issue "Legal Issues in Transfusion Medicine."
Being aware that the prime readership comes from the member countries of the AATM, and three of these member countries belong to the WHO Eastern Mediterranean Region (EMR) -Afghanistan, Iran, and Pakistan, we feel the need to comment on both Editorials as they reflect a general state of development of the blood supply and clinical use that deserves a focused attention and sustained support.
All countries have agreed to try to achieve universal health coverage (UHC) by 2030, as part of the Sustainable Development Goals (SDG). [3] UHC provides access to quality essential health services; safe, effective, and affordable essential medicines and vaccines; and protection from financial risk.
[4]
Blood and blood products are essential medicines, [5] and universal and timely access to these products, and their appropriate use, are essential components of good health care provision. Governments are responsible for ensuring the ethical and equitable procurement, distribution, and use of these products through the establishment of a nationally coordinated and effectively regulated blood supply. [6] It is the governments' core duty to protect and promote public health, also protect the fundamental rights and freedoms of individuals, which may be endangered by unethical practices of procurement or distribution. [7] Indeed, the blood and its components are invaluable and shall be shared on a voluntary and nonremunerated basis. The recipient therefore shall not be charged for the "gift of life" but be asked to contribute in the costs of the service of availability, accessibility, efficacy, and safety of the products produced from the invaluable source material "human blood." Since Landsteiner, [8] attention has been given to the many facets of the transfusion medicine diamond. The key elements of the provision of a safe and efficacious transfusion practice have been formulated and spread out over the world by WHO since the first World Health Assembly resolution in 1975 [9] and subsequent development and implementation of the Quality Management education materials in the 1990s and beyond. [10] Both editorials do not mention these principles which include the legal principles of product liability and consumer rights protection. WHO EMR has developed a 10-year regional strategic framework for blood safety and availability [11] that will contribute toward achieving UHC and SDG on health. The strategic framework was endorsed by 22 countries in the region, [12] including Afghanistan, Iran, and Pakistan The framework guides and advises countries on availability and safety of blood transfusion vein-to-vein along 5 key issues which include strengthening leadership and governance, coordination and collaboration through development of a centralized information management system, strengthen provision of safe blood and blood products, promote their appropriate clinical use, and strengthen quality management system throughout the transfusion chain including hemovigilance.
The importance of the message is in a strong legislative and regulatory framework (governance commitment) and competent leadership to implement and follow national standards (quality and technical) and guidelines for creating and sustaining public and clinical awareness on the principles of voluntary blood donation and rational clinical use of blood. In the approach, continued education to maintain and improve human capacity and competence plays a paramount role. The capital investment will assure availability and safety while saving costs of a fragmented, incoherent, poor, and unethical practice organization, based on a solid governance (legislative framework) and competent leadership.
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